Your browser doesn't support javascript.
loading
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.
Perlett, Landon; Smith, Eric E.
Affiliation
  • Perlett L; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
  • Smith EE; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: eesmith@ucalgary.ca.
Clin Geriatr Med ; 39(1): 135-149, 2023 02.
Article in En | MEDLINE | ID: mdl-36404026
ABSTRACT
Ideally, dementia care should be provided by a collaborative team. Eligible patients should be treated with the cognitive-enhancing medications, the cholinesterase inhibitors and memantine. For most of the common causes of dementia, there are no disease-modifying medications, with the exception that vascular dementia can be prevented by treating vascular risk factors to prevent stroke. There is hope that Alzheimer disease can be treated by using monoclonal antibodies that target amyloid beta, although more trials are needed. Holistic, patient-centered care can enhance quality and extend the time that the patient can live safely in the community.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dementia, Vascular / Alzheimer Disease / Cognitive Dysfunction Limits: Humans Language: En Journal: Clin Geriatr Med Journal subject: GERIATRIA Year: 2023 Document type: Article Affiliation country: Canadá

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dementia, Vascular / Alzheimer Disease / Cognitive Dysfunction Limits: Humans Language: En Journal: Clin Geriatr Med Journal subject: GERIATRIA Year: 2023 Document type: Article Affiliation country: Canadá